Discover 334 paid clinical trials in Mississippi. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Mississippi provides diverse clinical research opportunities, opening doors for healthy volunteers interested in paid studies, as well as people with specific health conditions to contribute to medical research. Research hubs in Jackson, Gulfport, and Hattiesburg are actively recruiting, granting participants access to innovative treatments and comprehensive care.
Filter
1
Filter results
Results: 334
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
for
Castration-Resistant Prostate Carcinoma,
Location: Millville DE, Lewes DE, Rehoboth Beach DE,
Sponsor: SWOG Cancer Research Network
Sex: Male
Age: 18+
Code: NCT06470243
Phase 3, Recruiting
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
for
Muscle Invasive Bladder Urothelial Carcinoma,
Location: Brewer ME, Gloucester MA, South Weymouth MA, Beverly MA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT05987241
Phase 2, Phase 3, Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Location: Halifax, Bangor ME, Scarborough ME, Boston MA,
Sponsor: PedAL BCU, LLC
Sex: All
Age: 0 - 22
Code: NCT04726241
Phase 1, Phase 2, Recruiting
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
for
Pancreatic Acinar Cell Carcinoma,
Location: Saint Johnsbury VT, Lebanon NH, Commack NY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04858334
Phase 2, Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Location: Boston MA, Providence RI, Burlington MA, New Haven CT,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT06119581
Phase 3, Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
for
Advanced Non-Small Cell Lung Cancer,
Location: South Weymouth MA, Boston MA, Brighton MA,
Sponsor: Mirati Therapeutics Inc.
Sex: All
Age: 18+
Code: NCT04613596
Phase 2, Phase 3, Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
for
Ganglioneuroblastoma, Nodular, Neuroblastoma
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 0 - 30
Code: NCT06172296
Phase 3, Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
for
Locally Advanced Lung Non-Small Cell Carcinoma,
Location: Portland ME, Scarborough ME, South Portland ME,
Sponsor: NRG Oncology
Sex: All
Age: 18+
Code: NCT05624996
Phase 3, Recruiting
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
for
Recurrent Lung Non-Small Cell Carcinoma,
Location: Brewer ME, Westerly RI, Manchester NH, Worcester MA,
Sponsor: SWOG Cancer Research Network
Sex: All
Age: 18+
Code: NCT05642572
Phase 2, Recruiting
Project: Every Child for Younger Patients With Cancer
for
Adrenal Gland Pheochromocytoma, Carcinoma In Situ,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 25
Code: NCT02402244
Recruiting
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
for
Endometrial Cancer
Location: Boston MA, Providence RI, Lebanon NH, Quebec,
Sponsor: AstraZeneca
Sex: Female
Age: 18+
Code: NCT06989112
Phase 3, Recruiting
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.